Genetron Health to Highlight Data from 18 Studies at ESMO 2020

Genetron Health to present data at ESMO 2020 relating to precision oncology diagnostic development initiatives across lung, gastrointestinal and other cancer types, and to bioinformatics development

BEIJING, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening and companion diagnostics development, and its collaborators will present data from 18 studies at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020 taking place on September 19-21.

The abstracts include 15 studies on translational medicine covering various cancer types and three studies on bioinformatics development. Data that will be highlighted at the ESMO Virtual Congress were generated in collaboration with more than 10 notable cancer centers and clinical hospitals in China. In summary, the abstracts are grouped by four topics as follows:

Chinese population’s genetic characteristics:

• Six studies (#3835, #3836, #3898, #3946, #3961, #3965) focus mainly on the characteristic analyses of high-frequency gene mutations and gene rearrangements in the Chinese population. These studies aim at gathering specific data for the Chinese population in order to design precision oncology therapies for the domestic market.  
• Three studies (#3434, #3915, and #3938) describe the genetic characteristics such as germline mutations, somatic mutations and precision treatment targets in Chinese patients with pancreatic ductal adenocarcinomas.

Immunotherapies:

• Two studies (#3943 and #4313) focus on the exploration of immunotherapy-associated molecular biomarkers. The Company has found that KMT2C/KMT2D genetic alterations can be used as prognostic indicators for immunotherapy in colorectal cancer and gastric cancer.
• One study (#4161) demonstrates the therapeutic potential of preoperative immunotherapy in combination with chemotherapy for patients with metastatic pancreatic ductal adenocarcinomas.

Biomarker discoveries:

• One study (#3888) uncovered tumor type-specific genetic variations that could serve as biomarkers for prognosis and perioperative monitoring in each tumor type.
• Two studies (#3845 and #4127) evaluated the clinical significance of ONECUT2 gene methylation in the prognosis and diagnosis of upper tract urinary carcinoma.             

Optimizing bioinformatics: